Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvorexant as an Adjunct to Buprenorphine in Fentanyl Users
NCT05145764Phase 2Completed
- Sponsor
- Johns Hopkins University
- Start
- Mar 2022
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in opioid use disorder (OUD) comparing Suvorexant with Placebo (2 arms). Primary endpoints: Total Sleep Time and Buprenorphine compliance at 25 days. Started Mar 2022; status: completed.
02
Drugs
suvorexant
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT05145764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05145764.